Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Inhibitors (Find 73 items)

Inhibitors

PJ-34

(344458-15-7)
A poly adenosine diphosphate-ribose polymerase inhibitor, attenuates chromate-induced nephrotoxicity. east cancer MCF-7.

Product List

Request for quotation , get quotes from more suppliers.

PD 168393

(194423-15-9)
PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC. target: EGFRIC 50: 0.7 nM [1](1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with >9-fold greater potency than PD 174265.[1](2) PD 168393 decrease the production of TNF-α and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes.[2](3) PD168393 completely inhibits AKT and

Product List

Request for quotation , get quotes from more suppliers.

PIK-294

(900185-02-6)
PIK-294 is a potent p110δ-selective inhibitor with an IC50 of 10 nM.

Product List

Request for quotation , get quotes from more suppliers.

PH797804

(586379-66-0)
PH-797804 is a novel N-phenylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer and is also known to exerts anti-inflammatory properties.

Product List

Request for quotation , get quotes from more suppliers.

PHA 767491 HYDROCHLORIDE

(845714-00-3)
Cdc7 kinase is a key regulator of the S-phase of the cell cycle. It is known to promote the activity of DNA replication origins in eukaryotic organisms. Inhibition of Cdc7 kinase causes blockade of DNA synthesis in human cell lines. Tumor cells are then funneled into the apoptotic pathway in a p53-independent manner. Pharmacological inhibition of Cdc7 kinase can be an effective strategy for the development of oncologic therapeutics useful for treatment of cancers. PHA-767491 is a potent inhibito

Product List

Request for quotation , get quotes from more suppliers.

PI3K/HDAC Inhibitor

(1339928-25-4)
CUDC-907 is a dual PI3K and HDAC inhibitor. Studies have shown CUDC-907 is able to enhance antitumor activity when combined with standard of care agents in multiple myeloma and B cell lymphoma xenograft models.

Product List

Request for quotation , get quotes from more suppliers.

Pacap 6-38

(143748-18-9)

Product List

Request for quotation , get quotes from more suppliers.

Pracinostat

(929016-96-6)
Pracinostat is a potent and orally active histone deacetylase (HDAC) inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. The selectivity of Pracinostat for tumor tissues makes it a promising therapeutic candidate for use in patients with advanced solid malignancies.

Product List

Request for quotation , get quotes from more suppliers.

PR-619

(2645-32-1)
PR 619 is a broad-range DUB inhibitor. A selective and general inhibitior of cellular DUB activity without direct impairment of proteasomal proteolysis. Used in the preparation of thiazolopyridines and bisthiazolopyridines.

Product List

Request for quotation , get quotes from more suppliers.

Small molecule inhibitors are a type of molecules that can interact with proteins and reduce the biological activity of target proteins, including enzyme inhibitors, transcription factor inhibitors, and ion channel blockers. It acts on popular signaling pathways, popular targets and popular research fields: MAPK, PI3K, JAK / STAT and other signaling pathways, HDAC, Aurora kinase, CDK and cell cycle regulators, integrase / protease, etc. Research fields such as epigenetics, CNS, GPCR, anti-virus, antibacterial / anti-inflammatory. It is an effective tool for cell biology research.

Source Inhibitors Raw Materials by Region

Frequently Asked Questions

What are Inhibitors in biochemical and pharmaceutical contexts?

Inhibitors are molecules that bind to enzymes or other biological targets to decrease or block their activity. In pharmaceutical research, enzyme inhibitors are widely used to modulate disease-related pathways, making them essential in drug discovery for conditions such as cancer, viral infections, and metabolic disorders. Common types include competitive, non-competitive, and irreversible inhibitors, each with distinct mechanisms of action.

How do enzyme inhibitors contribute to drug development?

Enzyme inhibitors play a critical role in drug development by selectively targeting disease-causing enzymes, thereby halting pathological processes. For example, protease inhibitors are used in HIV treatment, while kinase inhibitors are key in oncology therapies. Their specificity, potency, and pharmacokinetic properties make them valuable candidates in therapeutic pipelines, often serving as lead compounds during preclinical and clinical stages.

What are common applications of Inhibitors in life science research?

Inhibitors are extensively used in life science research for:1. Elucidating signaling pathways by selectively blocking key enzymes.2. Validating drug targets through functional studies.3. Serving as positive controls in high-throughput screening assays.4. Studying disease mechanisms in cellular and animal models.5. Developing diagnostic tools and companion biomarkers.Their versatility makes them indispensable in both academic and industrial R&D settings.

How can I verify the authenticity and quality of purchased Inhibitors?

To verify the authenticity and quality of Inhibitors, request a Certificate of Analysis (CoA) from the supplier, which should include HPLC or NMR data confirming identity and purity. Cross-reference the compound’s CAS number and structure with authoritative databases like PubChem or ChEMBL. Additionally, check if the supplier adheres to international quality standards (e.g., ISO 9001) and provides lot-specific testing data. Reputable vendors often offer sample testing or third-party validation reports upon request.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.